Advancing access to myeloma treatment: administration, side effects, and implications for survival

ONS News. 2006;21(8 Suppl):11-2.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Chemotherapy, Adjuvant
  • Health Services Accessibility
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Information Services
  • Lenalidomide
  • Multiple Myeloma / etiology
  • Multiple Myeloma / mortality
  • Multiple Myeloma / therapy*
  • Nurse's Role
  • Oncology Nursing / organization & administration*
  • Patient Education as Topic
  • Protease Inhibitors / therapeutic use
  • Pyrazines / therapeutic use
  • Radiotherapy, Adjuvant
  • Stem Cell Transplantation / methods
  • Stem Cell Transplantation / nursing
  • Survival Rate
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Immunosuppressive Agents
  • Protease Inhibitors
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Lenalidomide